Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions
Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenario...
Saved in:
Published in | CPT: pharmacometrics and systems pharmacology Vol. 7; no. 11; pp. 771 - 779 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.11.2018
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
ISSN | 2163-8306 2163-8306 |
DOI | 10.1002/psp4.12354 |
Cover
Loading…
Abstract | Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic (ROC) and clinical trial simulation (CTS) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low‐variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC/CTS methods for optimizing dose titration offer an individualized approach that leverages exposure‐response relationships. |
---|---|
AbstractList | Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic (ROC) and clinical trial simulation (CTS) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low-variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC/CTS methods for optimizing dose titration offer an individualized approach that leverages exposure-response relationships. Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics ( PK ), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic ( ROC ) and clinical trial simulation ( CTS ) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low‐variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC / CTS methods for optimizing dose titration offer an individualized approach that leverages exposure‐response relationships. Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic (ROC) and clinical trial simulation (CTS) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low-variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC/CTS methods for optimizing dose titration offer an individualized approach that leverages exposure-response relationships.Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic (ROC) and clinical trial simulation (CTS) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low-variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC/CTS methods for optimizing dose titration offer an individualized approach that leverages exposure-response relationships. |
Author | Gibbs, John P. Perez Ruixo, Juan Jose Perez Ruixo, Carlos Melhem, Murad Clements, John David Doshi, Sameer |
AuthorAffiliation | 1 Clinical Pharmacology and Modeling & Simulation Amgen Inc. Thousand Oaks California USA 4 Clinical Pharmacology Vertex Pharmaceuticals Boston Massachusetts USA 2 Clinical Pharmacology and Pharmacometrics Janssen Research and Development Beerse Belgium 3 Clinical Pharmacology and Pharmacometrics AbbVie North Chicago Illinois USA |
AuthorAffiliation_xml | – name: 4 Clinical Pharmacology Vertex Pharmaceuticals Boston Massachusetts USA – name: 2 Clinical Pharmacology and Pharmacometrics Janssen Research and Development Beerse Belgium – name: 3 Clinical Pharmacology and Pharmacometrics AbbVie North Chicago Illinois USA – name: 1 Clinical Pharmacology and Modeling & Simulation Amgen Inc. Thousand Oaks California USA |
Author_xml | – sequence: 1 givenname: John David surname: Clements fullname: Clements, John David email: clementj@amgen.com organization: Amgen Inc – sequence: 2 givenname: Juan Jose surname: Perez Ruixo fullname: Perez Ruixo, Juan Jose organization: Janssen Research and Development – sequence: 3 givenname: John P. surname: Gibbs fullname: Gibbs, John P. organization: AbbVie – sequence: 4 givenname: Sameer surname: Doshi fullname: Doshi, Sameer organization: Amgen Inc – sequence: 5 givenname: Carlos surname: Perez Ruixo fullname: Perez Ruixo, Carlos organization: Janssen Research and Development – sequence: 6 givenname: Murad surname: Melhem fullname: Melhem, Murad organization: Vertex Pharmaceuticals |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30246497$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kV1rHCEUhqWkNB_NTX9AEXpTApuqo87OTSFs-hEIJDTba3H0TGLq6FRnUvbf182kIQ2lXujB87wv52Mf7YQYAKE3lBxTQtiHIQ_8mLJK8Bdoj1FZLZYVkTtP4l10mPMtKafmhDbkFdqtCOOSN_Ue-vENDLg7SPhigKRHF67x6kYnbUZILo_O4JOg_Sa7jHWweOVdcEZ7vE6u3Feun3xRxYDHiM9CF1OPT2MGvHZjmhOnYFwuQX6NXnbaZzh8eA_Q98-f1quvi_OLL2erk_OF4XzJF01lBGXG1h0zsoWG6PIh67prtADRlT5oa-vW2hpkba0htgPWUCK0aCRdttUB-jj7DlPbgzUQSileDcn1Om1U1E79nQnuRl3HOyWZrKSkxeD9g0GKPyfIo-pdNuC9DhCnrBiltOZCCFbQd8_Q2zilMrFCMSnZUlK2pd4-reixlD97KMDRDJgUc07QPSKUqO2e1XbP6n7PBSbPYOPG-1mXbpz_t4TOkl_Ow-Y_5ury6pLPmt9fP7tG |
CitedBy_id | crossref_primary_10_1192_bjp_2023_27 crossref_primary_10_1002_psp4_12613 crossref_primary_10_1002_psp4_12464 |
Cites_doi | 10.1111/j.1365-2125.2001.00971.x 10.3348/kjr.2004.5.1.11 10.1158/1078-0432.CCR-03-0785 10.1248/yakushi.129.749 10.1002/psp4.12106 10.1148/radiology.143.1.7063747 10.1097/FTD.0000000000000061 10.1016/j.jacc.2005.06.061 10.1002/0471722146 10.1007/s11095-006-9202-3 10.1038/clpt.2009.199 10.1177/193229681100500127 10.1177/0091270004271945 10.2165/00003088-200948050-00002 10.1097/00007691-200406000-00019 10.1016/j.bios.2014.03.047 10.1007/s00280-011-1714-9 10.2165/00003088-200847080-00001 10.1177/0091270010377201 10.1081/BIP-120037192 10.2165/00003088-200544020-00002 10.1023/A:1020953107162 10.1093/clinchem/39.4.561 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 10.1097/FTD.0000000000000009 |
ContentType | Journal Article |
Copyright | 2018 The Authors published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. 2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2018 The Authors published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. – notice: 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. – notice: 2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1002/psp4.12354 |
DatabaseName | Wiley Online Library Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed Publicly Available Content Database CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 2163-8306 |
EndPage | 779 |
ExternalDocumentID | PMC6263661 30246497 10_1002_psp4_12354 PSP412354 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | 0R~ 1OC 24P 5VS 7X7 8FI 8FJ AAHHS AAZKR ABDBF ABUWG ACCFJ ACCMX ACGFS ACUHS ACXQS ADBBV ADKYN ADPDF ADRAZ ADZMN ADZOD AEEZP AEQDE AFKRA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK EBS EJD FYUFA GODZA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH ITC KQ8 M48 M~E O9- OK1 OVD PIMPY PQQKQ PROAC RNTTT RPM TEORI TUS UKHRP WIN AAYXX CITATION PHGZM PHGZT NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c4484-93c512cd7f2c6be90a3c5677f9a5e5f0001bd7bdd7e67ddc0dfe29105a59618b3 |
IEDL.DBID | M48 |
ISSN | 2163-8306 |
IngestDate | Thu Aug 21 18:26:40 EDT 2025 Fri Sep 05 09:22:20 EDT 2025 Fri Jul 25 06:07:08 EDT 2025 Thu Apr 03 07:02:53 EDT 2025 Thu Apr 24 22:58:23 EDT 2025 Tue Jul 01 02:21:37 EDT 2025 Wed Jan 22 16:46:13 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
License | Attribution-NonCommercial 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4484-93c512cd7f2c6be90a3c5677f9a5e5f0001bd7bdd7e67ddc0dfe29105a59618b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1002/psp4.12354 |
PMID | 30246497 |
PQID | 2266286122 |
PQPubID | 4368367 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6263661 proquest_miscellaneous_2111745552 proquest_journals_2266286122 pubmed_primary_30246497 crossref_primary_10_1002_psp4_12354 crossref_citationtrail_10_1002_psp4_12354 wiley_primary_10_1002_psp4_12354_PSP412354 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2018 |
PublicationDateYYYYMMDD | 2018-11-01 |
PublicationDate_xml | – month: 11 year: 2018 text: November 2018 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | CPT: pharmacometrics and systems pharmacology |
PublicationTitleAlternate | CPT Pharmacometrics Syst Pharmacol |
PublicationYear | 2018 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
References | 2009; 86 2011 2004; 26 2004; 5 1982; 143 2011; 5 2005; 44 2005; 45 2009; 48 2005; 46 2004; 10 2016; 5 2002; 29 1993; 39 2000 2008; 29 2004; 14 2013; 30 2008; 47 2014; 59 2014; 36 2014 2009; 129 2012; 69 2012; 66 1991; 148 2007; 24 1950; 3 2001; 52 2010; 50 1989 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_22_1 Perry P.J. (e_1_2_10_21_1) 1991; 148 Acuna C. (e_1_2_10_8_1) 2013; 30 e_1_2_10_1_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_11_1 e_1_2_10_32_1 Beal S. (e_1_2_10_30_1) 1989 Jelic I. (e_1_2_10_15_1) 2012; 66 Florkowski C.M. (e_1_2_10_20_1) 2008; 29 e_1_2_10_29_1 Bauer R. (e_1_2_10_31_1) 2011 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1 |
References_xml | – year: 2011 – volume: 59 start-page: 233 year: 2014 end-page: 238 article-title: Detection of the antiepileptic drug phenytoin using a single free‐standing piezoresistive microcantilever for therapeutic drug monitoring publication-title: Biosens. Bioelectron. – volume: 36 start-page: 606 year: 2014 end-page: 611 article-title: Trough concentration over 12.1 mg/l is a major risk factor of vancomycin‐related nephrotoxicity in patients with therapeutic drug monitoring publication-title: Ther. Drug Monit. – volume: 44 start-page: 147 year: 2005 end-page: 173 article-title: Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review publication-title: Clin. Pharmacokinet. – volume: 66 start-page: 157 year: 2012 end-page: 164 article-title: [Opatija study: observation of hemodialysis patients and titration of cera dose just switched from another erythropoiesis stimulating agent] publication-title: Acta Med. Croatica – volume: 39 start-page: 561 year: 1993 end-page: 577 article-title: Receiver‐operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine publication-title: Clin. Chem. – volume: 47 start-page: 487 year: 2008 end-page: 513 article-title: Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology publication-title: Clin. Pharmacokinet. – volume: 5 start-page: 484 year: 2016 end-page: 494 article-title: Population pharmacokinetics and pharmacodynamics of the calcimimetic etelcalcetide in chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis publication-title: CPT Pharmacometrics Syst. Pharmacol. – year: 1989 – volume: 29 start-page: 339 year: 2002 end-page: 363 article-title: Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris publication-title: J. Pharmacokinet. Pharmacodyn. – volume: 30 start-page: 585 year: 2013 end-page: 590 article-title: [Pharmacokinetics of vancomycin in children hospitalized in a critical care unit] publication-title: Rev. Chilena Infectol. – volume: 5 start-page: 192 year: 2011 end-page: 197 article-title: Diabetes and biomarkers publication-title: J. Diabetes Sci. Technol. – year: 2000 – volume: 29 start-page: S83 issue: suppl. 1 year: 2008 end-page: S87 article-title: Sensitivity, specificity, receiver‐operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests publication-title: Clin. Biochem. Rev. – volume: 52 start-page: 55s issue: suppl. 1 year: 2001 end-page: 59s article-title: Target concentration intervention: beyond y2k publication-title: Br. J. Clin. Pharmacol. – volume: 26 start-page: 331 year: 2004 end-page: 335 article-title: A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation publication-title: Ther. Drug Monit. – volume: 10 start-page: 3885 year: 2004 end-page: 3896 article-title: Rationale for biomarkers and surrogate end points in mechanism‐driven oncology drug development publication-title: Clin. Cancer Res. – volume: 3 start-page: 32 year: 1950 end-page: 35 article-title: Index for rating diagnostic tests publication-title: Cancer – volume: 45 start-page: 246 year: 2005 end-page: 256 article-title: Population pharmacokinetic analysis and simulation of the time‐concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis publication-title: J. Clin. Pharmacol. – year: 2014 – volume: 5 start-page: 11 year: 2004 end-page: 18 article-title: Receiver operating characteristic (ROC) curve: practical review for radiologists publication-title: Korean J. Radiol. – volume: 86 start-page: 667 year: 2009 end-page: 671 article-title: Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon‐like peptide‐2 analog in neonates and infants with short‐bowel syndrome publication-title: Clin. Pharmacol. Ther. – volume: 129 start-page: 749 year: 2009 end-page: 757 article-title: Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log‐binominal regression for febrile neutropenia publication-title: Yakugaku Zasshi – volume: 48 start-page: 301 year: 2009 end-page: 311 article-title: Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride publication-title: Clin. Pharmacokinet. – volume: 69 start-page: 447 year: 2012 end-page: 455 article-title: Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation publication-title: Cancer Chemother. Pharmacol. – volume: 24 start-page: 791 year: 2007 end-page: 802 article-title: Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation publication-title: Pharm. Res. – volume: 148 start-page: 231 year: 1991 end-page: 235 article-title: Clozapine and norclozapine plasma concentrations and clinical response of treatment‐refractory schizophrenic patients publication-title: Am. J. Psychiatry – volume: 50 start-page: 75s year: 2010 end-page: 90s article-title: Exposure‐response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis publication-title: J. Clin. Pharmacol. – volume: 36 start-page: 335 year: 2014 end-page: 344 article-title: Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain publication-title: Ther. Drug Monit. – volume: 143 start-page: 29 year: 1982 end-page: 36 article-title: The meaning and use of the area under a receiver operating characteristic (ROC) curve publication-title: Radiology – volume: 14 start-page: 451 year: 2004 end-page: 467 article-title: Simulating titration to goal clinical trials with statins publication-title: J. Biopharm. Stat. – volume: 46 start-page: 1322 year: 2005 end-page: 1330 article-title: Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia publication-title: J. Am. Coll. Cardiol. – ident: e_1_2_10_5_1 doi: 10.1111/j.1365-2125.2001.00971.x – volume: 66 start-page: 157 year: 2012 ident: e_1_2_10_15_1 article-title: [Opatija study: observation of hemodialysis patients and titration of cera dose just switched from another erythropoiesis stimulating agent] publication-title: Acta Med. Croatica – volume: 29 start-page: S83 issue: 1 year: 2008 ident: e_1_2_10_20_1 article-title: Sensitivity, specificity, receiver‐operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests publication-title: Clin. Biochem. Rev. – ident: e_1_2_10_19_1 doi: 10.3348/kjr.2004.5.1.11 – ident: e_1_2_10_13_1 doi: 10.1158/1078-0432.CCR-03-0785 – ident: e_1_2_10_4_1 doi: 10.1248/yakushi.129.749 – ident: e_1_2_10_17_1 doi: 10.1002/psp4.12106 – ident: e_1_2_10_27_1 doi: 10.1148/radiology.143.1.7063747 – ident: e_1_2_10_10_1 doi: 10.1097/FTD.0000000000000061 – ident: e_1_2_10_1_1 doi: 10.1016/j.jacc.2005.06.061 – ident: e_1_2_10_32_1 – ident: e_1_2_10_22_1 doi: 10.1002/0471722146 – volume-title: NONMEM Users Guide: Introduction to nonmem 7.2 year: 2011 ident: e_1_2_10_31_1 – volume: 148 start-page: 231 year: 1991 ident: e_1_2_10_21_1 article-title: Clozapine and norclozapine plasma concentrations and clinical response of treatment‐refractory schizophrenic patients publication-title: Am. J. Psychiatry – ident: e_1_2_10_3_1 doi: 10.1007/s11095-006-9202-3 – ident: e_1_2_10_24_1 doi: 10.1038/clpt.2009.199 – ident: e_1_2_10_14_1 doi: 10.1177/193229681100500127 – ident: e_1_2_10_2_1 doi: 10.1177/0091270004271945 – ident: e_1_2_10_16_1 doi: 10.2165/00003088-200948050-00002 – ident: e_1_2_10_12_1 doi: 10.1097/00007691-200406000-00019 – ident: e_1_2_10_11_1 doi: 10.1016/j.bios.2014.03.047 – ident: e_1_2_10_18_1 doi: 10.1007/s00280-011-1714-9 – ident: e_1_2_10_7_1 doi: 10.2165/00003088-200847080-00001 – volume: 30 start-page: 585 year: 2013 ident: e_1_2_10_8_1 article-title: [Pharmacokinetics of vancomycin in children hospitalized in a critical care unit] publication-title: Rev. Chilena Infectol. – ident: e_1_2_10_26_1 doi: 10.1177/0091270010377201 – ident: e_1_2_10_25_1 doi: 10.1081/BIP-120037192 – ident: e_1_2_10_6_1 doi: 10.2165/00003088-200544020-00002 – volume-title: NONMEM User's Guides year: 1989 ident: e_1_2_10_30_1 – ident: e_1_2_10_23_1 doi: 10.1023/A:1020953107162 – ident: e_1_2_10_28_1 doi: 10.1093/clinchem/39.4.561 – ident: e_1_2_10_29_1 doi: 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 – ident: e_1_2_10_9_1 doi: 10.1097/FTD.0000000000000009 |
SSID | ssj0000740190 |
Score | 2.1278763 |
Snippet | Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 771 |
SubjectTerms | Algorithms Clinical trials Drug dosages Efficiency Studies |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0vvgirZ-xVUaUgtLYXLKbTZ5EWksR1INe4d7CfgUPa5I214f-953Z7OU8Kn0L2Qn5mNmZX2Z3fsPYB5MZWbrExnVdq5iLLImVnqg419KaiU1V7nO6P37mp-f8-1zMQ8KtD9sqVz7RO2rbGsqRHyJMoCrKSZp-6S5j6hpFq6uhhcZD9shTl6E9y7kccywJtZsrk5GVND3s-o5_pvJQvhmH7oDLu3sk_8WuPvicbLMnATXC10HNO-yBa56y_elAO31zALN1FVV_APswXRNS3zxjfxAbOtp_Ab864lDGaAVHG0TNsOImAdVYCFyhFzAj64Szxd_Q4wuWLQz1S3Dc9g5mi0C6C8ehVU__nJ2ffJsdncahyUJs8M-Mx2VmMOYbK-vU5NqVicITuZR1qYQTNWFAbaW2VrpcWmsSW7sUMYZQgprF6OwF22raxr1ikBUqtXRhgYG_1rnWBXrPglt0uEWSmYh9XH3yygQGcmqEcVEN3MlpReqpvHoi9n6U7Qbejf9K7a00V4W511drS4nYu3EYZw0thajGtdcogy5eciEEyrwcFD3eJsOnz3kpIyY3TGAUIEbuzZFm8dszcxO1DwKeiH3yxnLPk1fTsyn3R6_vf4dd9hgxWjGUP-6xreXVtXuDOGip33pjvwW2ggtq priority: 102 providerName: ProQuest – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fS9xAEB6sffGl1NbatCpbWoSK0dxmN5uAL0UrUqgGPMG3sL9Cj9rc0ZwP_ved2eRyHpZC30J2liyZnZkvk51vAD7Z1KrCJy6u61rHQqZJrM1Ix5lRzo4c11nI6X6_zC5uxLdbebsGJ4tamI4fYki4kWUEf00Grk17vCQNnbUzcUSVnuIZPKfaWmrcwEU5ZFgSajYXkiwcQUecIzge-En58XL6akR6AjOfnpZ8jGJDGDp_CS96_Mi-dArfhDXfvIL9siOgfjhk42U9VXvI9lm5pKZ-eA0_ESV6OonBrmbEpoxxi52uUDazBUsJ041jPWvoHRvTPmXXk199ty82n7KukomdTVvPxpOefped9U172i24Of86Pr2I-3YLscVvNBEXqcXob52quc2MLxKNNzKl6kJLL2tCg8Yp45zymXLOJq72HNGG1JLaxpj0Daw308a_BZbmmjuamCMEqE1mTI5-NBcOXW-epDaCz4tXXtmei5xaYtxVHYsyr0g9VVBPBB8H2VnHwPFXqZ2F5qreCtsKoSVV3o44j-DDMIz2Qz9FdOOn9yiDzl4JKSXKbHeKHh6T4uozUagI1MoWGASIm3t1pJn8CBzdRPKD0CeCg7BZ_rHyqrwuRbh69z_C72EDsVvelUXuwPr8973fRXw0N3vBDP4AiFEOJg priority: 102 providerName: Wiley-Blackwell |
Title | Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpsp4.12354 https://www.ncbi.nlm.nih.gov/pubmed/30246497 https://www.proquest.com/docview/2266286122 https://www.proquest.com/docview/2111745552 https://pubmed.ncbi.nlm.nih.gov/PMC6263661 |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ra9swED_6gNEvY93Taxc0NgobdevYsmV_KGPrY2XQzqwJ5JvRyywsc9I6heW_30mW3YR2-yKMdcJCd9L9JOt-B_BeRpJlOlB-WZbcp3EU-Fz0uZ8IpmRfhTyxZ7oXl8n5kH4bxaM1aPN3ugGsH9zamXxSw5vJwZ_rxSec8EeOQPRwVs_ogYn5pOuwiR4pMZuwCwfz7Yps0s5lQcdOutxkCx5F6KcSamifll3TPbx5_9rkMpy1_ujsCTx2QJJ8bjS_DWu6egp7ecNEvdgng7vAqnqf7JH8jqN68Qx-IVzU5koG-T4ztMrowMjxCnczaelKCK8UcfShEzIwBkuuxr9d2i8yn5ImpImcTGtNBmPHw0tOXPae-jkMz04Hx-e-y7vgS9ysUT-LJMIAqVgZykToLOD4ImGszHis49LAQqGYUIrphCklA1XqEGFHzGOTP0ZEL2Cjmlb6FZAo5aEyDVMc41IkQqS4oKZU4RqcBpH04EM75IV0pOQmN8akaOiUw8JoqrCa8uBdJztrqDgelNptNVe01lQgxjQhuP0w9OBtV40Tyfwd4ZWe3qIMrvqMxnGMMi8bRXefaS3EA7ZiAp2AIeleranGPy1Zt2H7QQzkwUdrLP_peZFf5dQ-vf5nB3ZgCxFb2gRD7sLG_OZWv0FUNBc9WA9pjiUbsR5sfjm9zH_07AkDll9H_Z6dEn8BrvESkw |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6V9AAXxBtDgUVAJVBNnfXaax8QgqZVStsQUVfqzezLIqLYBqdC-VP8Rmb9ClFRb71Z9thee2Z2vn3MNwAvla94bDztZlkmXBb4nivkULih5FoNNRVhPad7NAnHJ-zTaXC6Bn-6XBi7rbLrE-uOWhfKzpFvI0ywWZRDSt-XP11bNcqurnYlNBqzODCL3zhkq97tj1C_ryjd2012xm5bVcBVOBRhbuwrDHJK84yqUJrYE3gi5DyLRWCCzIIeqbnUmpuQa608nRmKQTUQga2OIn187jVYZzajdQDrH3cn0y_9rI5nC9zFXs-DSrfLqmRvbUIqW418F-DsxV2Z_6LlOtzt3YKbLU4lHxrDug1rJr8Dm9OG6HqxRZJl3la1RTbJdEmBvbgL3xGNGrvjg3wuLWszxkeys0INTTo2FCJyTVp20jOSWH8gx7MfbVUxMi9IkzFFRkVlSDJraX7JqC0OVN2DkytRwH0Y5EVuHgLxI0G1vTFCqJHJUMoI--uIaeziI89XDrzufnmqWs5zW3rjLG3Ymmlq1ZPW6nHgRS9bNkwf_5Xa6DSXtt5epUvbdOB5fxn91C6-iNwU5yiDQYWzIAhQ5kGj6P41PrY-ZDF3gK-YQC9gOcBXr-SzbzUXuCUTQojlwJvaWC5peTo9nrL66NHl3_AMro-To8P0cH9y8BhuIEKMmuTLDRjMf52bJ4jC5vJpa_oEvl61t_0F6_BKKw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIiEuFW9SChgBlUBNN-s4cXJACHVZtRRKpG6lvQW_oq4oSdpshfav8esY57WsinrrLYonL8-M57Pj-QbgjfIVj42n3SzLhMsC33OFHAo3lFyroaYirNd0vx2F-yfsyzSYrsGfLhfGbqvsxsR6oNaFsmvkA4QJNotySOkga7dFJKPxx_LctRWk7J_WrpxGYyKHZvEbp2_Vh4MR6votpePPk719t60w4CqcljA39hUGPKV5RlUoTewJPBFynsUiMEFmAZDUXGrNTci1Vp7ODMUAG4jAVkqRPt73FtzmPqIq9CU-5f36jmdL3cVez4hKB2VVsl2bmspWY-AVYHt1f-a_uLkOfON7sNEiVvKpMbH7sGbyB7CdNJTXix0yWWZwVTtkmyRLMuzFQ_iJuNTYvR_ke2n5mzFSkr0VkmjS8aIQkWvS8pSekYn1DHI8-9XWFyPzgjS5U2RUVIZMZi3hLxm1ZYKqR3ByI93_GNbzIjdPgfiRoNpeGCHoyGQoZYQjd8Q0DvaR5ysH3nVdnqqW_dwW4ThLG95mmlr1pLV6HHjdy5YN58d_pbY6zaWt31fp0kodeNU3o8fa3zAiN8UlymB44SwIApR50ii6f4yPbx-ymDvAV0ygF7Bs4Kst-ey0ZgW3tEIIthx4XxvLNW-eJscJq482r_-Gl3AHfSz9enB0-AzuIlSMmizMLVifX1ya5wjH5vJFbfcEfty0o_0FS6FM8g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Receiver+Operating+Characteristic+Analysis+and+Clinical+Trial+Simulation+to+Inform+Dose+Titration+Decisions&rft.jtitle=CPT%3A+pharmacometrics+and+systems+pharmacology&rft.au=Clements%2C+John+David&rft.au=Perez+Ruixo%2C+Juan+Jose&rft.au=Gibbs%2C+John+P&rft.au=Doshi%2C+Sameer&rft.date=2018-11-01&rft.eissn=2163-8306&rft.volume=7&rft.issue=11&rft.spage=771&rft_id=info:doi/10.1002%2Fpsp4.12354&rft_id=info%3Apmid%2F30246497&rft.externalDocID=30246497 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2163-8306&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2163-8306&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2163-8306&client=summon |